CV Sciences Reports 2025 Results and Profitability Improvements

CV Sciences ( (CVSI) ) has provided an update.

CV Sciences reported its fiscal 2025 and fourth-quarter 2025 results on March 26, 2026, showing revenue declined to $13.8 million from $15.7 million in 2024, largely due to out-of-stock issues and restrictive regulations, even as 39% of annual net revenue came from products launched since 2023. The company significantly improved profitability metrics, lifting gross margin to 49.0%, cutting operating expenses by 17.2%, narrowing its operating loss to $0.5 million and adjusted EBITDA loss to $0.3 million for the year, and delivering positive adjusted EBITDA in the fourth quarter, supported by new product launches and a completed debt restructuring that strengthened its financial position.

Fourth-quarter 2025 sales held at $3.3 million, up slightly sequentially on higher B2B revenue, while the quarterly operating loss shrank to $0.1 million versus $0.6 million a year earlier, underscoring progress toward sustainable profitability. With a modest year-end cash balance of $0.3 million, management emphasized continuing efficiency gains, consistent positive cash flow and the use of strategic, bolt-on acquisitions to leverage its platform and enhance long-term shareholder value and competitive standing in the wellness and hemp-extract markets.

The most recent analyst rating on (CVSI) stock is a Sell with a $0.04 price target. To see the full list of analyst forecasts on CV Sciences stock, see the CVSI Stock Forecast page.

Spark’s Take on CVSI Stock

According to Spark, TipRanks’ AI Analyst, CVSI is a Neutral.

The score is held back primarily by weak fundamentals—sharp revenue contraction, ongoing losses, and thin/negative free cash flow—despite some margin improvement and manageable leverage. Technical indicators are neutral with modest positive momentum, but valuation remains unattractive due to negative earnings, and the latest company update highlights regulatory and demand pressures even as it pursues product launches and growth initiatives.

To see Spark’s full report on CVSI stock, click here.

More about CV Sciences

CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals, plant-based foods and hemp extracts, along with other science-backed natural ingredients and products. Its +PlusCBD line is a leading hemp-extract brand in the U.S. natural products market, while +PlusHLTH targets performance and vitality, Cultured Foods serves plant-based consumers in Europe, and Elevated Softgels manufactures encapsulated supplements and tinctures for the nutrition industry.

Average Trading Volume: 1,216,436

Technical Sentiment Signal: Strong Sell

Current Market Cap: $6.06M

For detailed information about CVSI stock, go to TipRanks’ Stock Analysis page.